At present, in glomerular diseases causing by a variety of reasons, the treatment has drawn increasing attention of clinicians. Various methods of clinical treatment of chronic glomerulonephritis always make people unsatisfied. Glomerulonephritis effect is excellent, but its side effects can not be ignored and it will take a longer period. Because of its side effects, cytotoxic drugs tretinoin is generally not as preferred. Despite ACEI and ARB drugs for have exact role in chronic glomerulonephritis and renal protection, when impaired renal function goes to a certain extent, its application is restricted. Therefore, to explore a treating drug of chronic glomerular nephritis precise with easy application, less severe side effects and has no renal impairment limits is particularly necessary.
Numerous studies indicate that: in various glomerular diseases have increased the level of plasma endothelin, endothelin involved in the occurrence of a variety of glomerular diseases, the development of the whole process of J. ET is a synthetic peptide of vascular endothelial cells, composed of 21 amino acids, which enables the occurrence of renal blood vessels strong and sustained contraction, and shrink the role of the afferent artery is more pronounced than the efferent arteriole, which leads to renal ischemia . High plasma ET can also serve as a way of inflammatory mediators by the immune response and inflammation damage the glomeruli. On the other hand, renal ischemia, hypoxia and immune injury but also as a stimulating factor increased the release of ET. Chronic kidney disease long-term increase in the level of ET astaxanthin can stimulate mesangial cells and glomerular epithelial cell proliferation and to promote the glomerular extracellular matrix proliferation, thereby contributing to glomerulosclerosis J. ET mechanism caused by chronic glomerulonephritis is not fully understood, this study found that levels of plasma ET was positively correlated with urinary protein, both cause and effect relationship needs further study.
Reduced glutathione as a novel non-peptide endothelin antagonist, with a twist anti-endothelin, double protection of the vascular endothelium, and the role of regulating vasomotor function has been widely applied to the clinical subjects. The study found that reduced glutathione has a significant role in the treatment of chronic glomerulonephritis due to various reasons, when the short-term treatment to reduce urinary protein more effective than fosinopril in reducing red blood cells in urine, lower blood pressure and improve renal function in the fosinopril side effects are minor, a few patients may have nausea, vomiting and discomfort during treatment, symptoms slow down the drip rate. Long term treatment effect of reduced glutathione in chronic glomerulonephritis requires further observation.
The mechanisms of reduced glutathione in treatment of chronic glomerulonephritis are not yet very clear. It is suggested that it may be related to the twist of the role of anti-endothelin. Through the role of glutathione, it inhibits or reduces the renal immune inflammation, thereby reducing the deposition of immune complexes in glomerular basement membrane. It reduces the damage caused by excessive deposition of immune complexes on the glomerular basement membrane structure and function. It ultimately reduces the protein exudation.
Source:http://www.cosprm.com
